ST2 (Suppression Of Tumorigenicity)

The IL-33/ST-2 signaling pathway contributes to the pathogenesis of hepatic fibrosis and immunological dysregulation in AE by influencing eosinophil function. Combined intervention targeting this pathway and albendazole administration confers enhanced therapeutic efficacy for AE, encompassing antifibrotic action, liver function recovery, and immune modulation.

Soluble ST2 shows particular promise as a biomarker reflecting disease activity and cardiac stress. Targeted modulation of IL-33/ST2 signaling, guided by disease phase and biomarker profiles, could represent a next-generation therapeutic approach to prevent CAAs in KD.

The discharge-phase biomarker model outperforms conventional scores,a model using D-dimer, procalcitonin, and lymphocyte percentage is a practical alternative. Integrating recovery-phase biomarkers into discharge planning offers a precision medicine strategy to optimize post-discharge management and reduce adverse outcomes.

In particular, numerous computer-aided drug design (CADD) studies have focused on the IL-33/ST2 complex and its role in maintaining intestinal barrier function. This review provides a comprehensive overview of the IL-33/ST2 axis in IBD, on mucosal healing and potential modulation strategies, such as computational approaches.

These findings suggest that subclinical myocardial changes may persist following RT, although the clinical significance of subclinical myocardial changes remains uncertain and warrants further investigation.

P1, N=24, Recruiting, Georgetown University | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

Collectively, these biomarkers represent complementary windows into the pathophysiology of HFpEF. A multimarker strategy that integrates markers of wall stress, injury, inflammation, and fibrosis may enhance diagnostic precision and risk stratification in elderly patients, guiding more personalized approaches to management.

Recent therapeutic strategies targeting its receptor (suppression of tumorigenicity 2) and signaling pathways are under investigation, with early clinical trials focusing on anti-IL-33 receptor antibodies and signaling pathway inhibitors. However, challenges remain regarding immune-related side effects, and further clinical studies are needed to ensure the safety and efficacy of IL-33-targeted therapies.

By promoting a regulatory microglial state and balancing the IL-10/IL-1β ratio, IL-33 prevents neuroinflammation and neurodegeneration. Our data highlight the pharmacological potential of the IL-33/ST2 axis in counteracting amyloid-related pathologies.

Cox proportional hazards regression model analysis further confirmed that level of CS cfDNA at the time of admission was an independent predictor of HF following STEMI, with a hazard ratio (HR) of 2.804 and a 95% CI of 1.086-7.243, achieving statistical significance at p = 0.035. There was a significant positive association between CS cfDNA levels and cardiac injury biomarkers (such as cTnI and sST2). CS cfDNA levels may represent a promising and important biomarker for predicting the occurrence of HF after STEMI, providing novel strategies for clinical management and prognostic evaluation of patients.

GDF-15 >1,400 pg/mL independently predicted adverse outcomes (HR 2.03, p = 0.046). GDF-15 and suPAR provide incremental prognostic value for short-term risk stratification after transcatheter tricuspid valve intervention.